Efficacy and Safety of Abiraterone Acetate Plus Prednisone vs Cabazitaxel as a Subsequent Treatment After First-Line Docetaxel in mCRPC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and Safety of Abiraterone Acetate Plus Prednisone vs. Cabazitaxel as a Subsequent Treatment After First-Line Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Results From a Prospective Observational Study (CAPRO)
BMC Cancer 2019 Aug 05;19(1)766, J Puente, A González-Del-Alba, N Sala-Gonzalez, MJ Méndez-Vidal, A Pinto, Á Rodríguez, JM Cuevas Sanz, JR Muñoz Del Toro, E Useros Rodríguez, Á García García-Porrero, S VázquezFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.